The Power of Patients: How Advocacy Groups are Architecting the Friedreich’s Ataxia Drug Market In traditional pharmaceutical markets—such as those for statins or antidepressants—the patient is the end consumer, arriving at the very end of a multi-billion-dollar corporate supply chain. In the rare disease space, this dynamic is entirely inverted. In the Friedreich’s Ataxia Drug Market, patients and their families are not just passive consumers; they are the fundamental...
0 Поделились
1835 Просмотры